Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Non-Current Deffered Revenue (2016 - 2025)

Sonoma Pharmaceuticals has reported Non-Current Deffered Revenue over the past 15 years, most recently at $4000.0 for Q2 2025.

  • For Q2 2025, Non-Current Deffered Revenue fell 93.75% year-over-year to $4000.0; the TTM value through Jun 2025 reached $4000.0, down 93.75%, while the annual FY2025 figure was $17000.0, 80.46% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2025 was $4000.0 at Sonoma Pharmaceuticals, down from $17000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $229000.0 in Q1 2021 and troughed at $4000.0 in Q2 2025.
  • A 5-year average of $121277.8 and a median of $130000.0 in 2022 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: dropped 6.25% in 2021 and later crashed 93.75% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $190000.0 in 2021, then crashed by 32.63% to $128000.0 in 2022, then fell by 21.09% to $101000.0 in 2023, then plummeted by 70.3% to $30000.0 in 2024, then crashed by 86.67% to $4000.0 in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for SNOA at $4000.0 in Q2 2025, $17000.0 in Q1 2025, and $30000.0 in Q4 2024.